- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
HYL
BRU
Week ended 07 Aug 2026
Weekly Investor Report
Hyloris Pharmaceuticals SA · Healthcare · Biotechnology
Latest close
4.56 EUR
-4.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -19.2% below the Trend Line and sits at 8.6% of its 52-week range. The latest completed week returned -4.6%, after a -1.9% four-week move. The latest news-sentiment score is 50/100.
Setup score
25
out of 100
Latest Close
4.56 EUR
7 Aug 2026
1W Return
-4.6%
latest completed week
4W Return
-1.9%
short-term follow-through
12W Return
-12.6%
quarterly tape
Trend Breadth
28.8%
15 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.6%
Latest completed week; four-week move -1.9%.
Indicator stack
16/45
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.52%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -19.2% below the Trend Line and sits at 8.6% of its 52-week range. The latest completed week returned -4.6%, after a -1.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1212-week average 0.07
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.9% over four weeks, -12.6% over 12 weeks, and -29.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year15
Trend breadth28.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.32Latest activity-pressure read.
Pressure change11.4%Four-week change in activity pressure.
Leadership-29.88Latest relative-leadership reading.
RS change-2.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 2 relevant articles.
0 positive · 2 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-45.7%Distance below the 52-week high.
13-week volatility2.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2617 weeks finished lower.
Best week+25.4%Week of 17 Apr.
Worst week-11.5%Week of 6 Mar.
Latest week-4.6%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains5
Flat weeks0
Modest losses7
Sharp losses10
Recent vol2.9%13-week weekly-return volatility.
Base vol7.2%52-week weekly-return volatility.
Up/down split19/31Count of positive and negative weeks in the 52-week window.
Average skew6.3% / -4.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorBE Healthcare
4-week rank4 / 12
Group average-2.8%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD25.0%positive activity pressure
RS8.3%positive relative leadership
Four-week leaders
IndustryBE Biotechnology
4-week rank4 / 9
Group average-1.1%
Trend breadth11.1%
Trend11.1%active weekly trend signals
MD22.2%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.12; No reversal markers Next-Week ExpectancyNegative 41.52%Next-week expectancy is negative with a 41.52% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 2 relevant articles.
Kye Pharmaceuticals partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 4.56 EUR | -4.6% | 5.64 EUR | 7.83 EUR | -0.32 | -29.88 | 12.1K | Off |
| 31 Jul 2026 | 4.78 EUR | 4.8% | 5.76 EUR | 7.88 EUR | -0.26 | -26.05 | 9.1K | Off |
| 24 Jul 2026 | 4.56 EUR | -1.3% | 5.84 EUR | 7.92 EUR | -0.35 | -30.80 | 2.5K | Off |
| 17 Jul 2026 | 4.62 EUR | -0.6% | 5.88 EUR | 7.96 EUR | -0.28 | -29.39 | 5.8K | Off |
| 10 Jul 2026 | 4.65 EUR | 2.9% | 5.93 EUR | 8.01 EUR | -0.37 | -29.25 | 31.1K | Off |
| 3 Jul 2026 | 4.52 EUR | -2.8% | 5.97 EUR | 8.05 EUR | -0.61 | -34.42 | 4.7K | Off |
| 26 Jun 2026 | 4.65 EUR | 0.9% | 6.02 EUR | 8.09 EUR | -0.73 | -32.35 | 2.1K | Off |
| 19 Jun 2026 | 4.61 EUR | -2.9% | 6.06 EUR | 8.13 EUR | -0.83 | -32.45 | 665 | Off |
| 12 Jun 2026 | 4.75 EUR | -5.0% | 6.12 EUR | 8.17 EUR | -0.89 | -32.03 | 4.8K | Off |
| 5 Jun 2026 | 5.00 EUR | -0.4% | 6.15 EUR | 8.22 EUR | -0.93 | -26.97 | 3.3K | Off |
| 29 May 2026 | 5.02 EUR | 0.6% | 6.16 EUR | 8.26 EUR | -0.97 | -27.25 | 10.8K | Off |
| 22 May 2026 | 4.99 EUR | -4.4% | 6.19 EUR | 8.30 EUR | -1.00 | -28.23 | 23.0K | Off |
| 15 May 2026 | 5.22 EUR | 1.2% | 6.21 EUR | 8.34 EUR | -0.98 | -23.75 | 13.2K | Off |
| 8 May 2026 | 5.16 EUR | 6.4% | 6.23 EUR | 8.38 EUR | -0.85 | -24.98 | 18.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.